GlobeNewswire

Juniper Networks Becomes Global Sponsor of World Robot Olympiad

Dela

Global competition that enables tens of thousands of young people to develop invaluable automation and programming skills now includes Engineering Simplicity award

 

SUNNYVALE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that it has become the global technology partner of the World Robot Olympiad(TM) Association (WRO®), a non-profit organization that focuses on the hands-on development of robotics within STEM (Science, Technology, Engineering, Math) education on a worldwide scale. In a multi-year agreement, Juniper will work closely with WRO to promote, stage and further develop this global competition that attracts tens of thousands of young people.

As part of its involvement in the competition, Juniper will be sponsoring a new trophy at this year's finals, WRO 2018, known as the Juniper Networks' Engineering Simplicity Honors Award. Juniper will judge teams in the Regular category at the finals, across all age groups, on the boldness, creativity and simplicity of their robot-led solutions. Overall, the WRO competition encourages participating teams to solve challenges and complex problems using mathematics, computer programming and coding skills, as well as exploring the principles of automation. It also fosters other important life skills including teamwork, perseverance, learning from mistakes and creative thinking.

Juniper is currently sponsoring a short documentary film looking at the human stories behind some of the teams and their paths to WRO 2018. The company is working in conjunction with the accomplished filmmaker and director James Redford, who is renowned for making documentary films that focus on personal, solution-based stories addressing vexing social and environmental challenges.

News Highlights:

  • Each year, at least 23,000 teams from more than 70 countries take part in WRO's competition. This involves approximately 100,000 young people, ranging from six to 25 years old.
  • The competition comprises several categories across the age group span, including Regular (a themed category), Open (to drive innovation and creativity), a robotic football tournament, an Advanced Robotics Challenge for students aged 19-25, and WeDo, a starter class for children aged 6-10.
  • Country heats roll up to a national final, with the winners going forward to the global finals.
  • The competition focuses on a specific theme that is relevant to a prevailing global issue - this year it is Food Matters. Challenges are tailored specifically to the theme, enabling competitors to develop ambitious, yet simple, automated solutions.
  • WRO, founded in 2004, hosts the Finals in a different country each year. In 2018, the global finals will be in Chiang Mai, Thailand (November 16-18) and they will take place in Hungary in 2019.

Supporting Quotes

"In WRO, we see robotics as a wonderful platform for giving young people around the world an opportunity to be hands-on with STEM. We see the teams adopt new technology when developing fully autonomous robots and they apply engineering processes when designing prototypes before completing the challenges. They quickly get absorbed in coming up with original solutions to complex problems.

"Bringing Juniper Networks on board as a global premium partner enables us to tap into its heritage and experience as an engineering and automation pioneer. Juniper will provide practical support and inspiration for young people as they embark upon their STEM-driven journeys toward fulfilling careers."
- Claus Ditlev Christensen, secretary-general at World Robot Olympiad Association Ltd.

"My work is all about finding and telling inspiring stories that show the best in people. When I heard about WRO's competition from Juniper, the talent, passion and commitment of so many young people truly excited me. Many teams come from challenging backgrounds with less-than-ideal education provision, so their achievements are all the more impressive. It is also great to be working with a technology innovator like Juniper to help the next generation think about their STEM education in such a creative way."
- James Redford, film and documentary maker

"In the digital age, networks are the lifeblood of every community, every government and every economy. Automation has become a key enabler of such technology, functioning alongside humans to create and operate networks that can scale, flex and protect, dynamically adapting in nanoseconds to deliver rich services. Ironically, a pressing shortage of skilled technologists is likely to increase even more in the future, putting at risk the potential of intelligent networks.

"It is imperative that the upcoming generations understand the importance of automation - Artificial Intelligence, Machine Learning, virtualization - in order to take technology forward into their future. Juniper Networks is proud to be the global technology partner of the WRO Finals in 2018 and beyond, as it is the perfect nurturing environment for tomorrow's automation innovators."
- Mike Marcellin, chief marketing officer at Juniper Networks

Additional Resources: 

About Juniper Networks
Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Media Relations
Penny Still
Juniper Networks
Tel: +44 (0) 1372 385 692
Email: pstill@juniper.net




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Networks via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum